Familial adenomatous polyposis patients have high levels of arachidonic acid and docosahexaenoic acid and low levels of linoleic acid and α-linolenic acid in serum phospholipids

International Journal of Cancer

Volumn 120, Issue 3, 2007, Pages 632-637

  Almendingen, Kari ^a,b   Høstmark, Arne T ^c   Fausa, Olav ^b   Mosdøl, Annhild ^d   Aabakken, Lars ^b   Vatn, Morten H ^b,c  

^a AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^b OSLO UNIVERSITY HOSPITAL   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Arachidonic acid; Cancer; Docosahexaenoic acid; FAP; Fatty acids

Indexed keywords

ARACHIDIC ACID; ARACHIDONIC ACID; DOCOSAHEXAENOIC ACID; ICOSAPENTAENOIC ACID; LINOLEIC ACID; LINOLENIC ACID; OLEIC ACID; PALMITIC ACID; PALMITOLEIC ACID; PHOSPHOLIPID; STEARIC ACID;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD SAMPLING; CANCER RISK; CHILD; CLINICAL ARTICLE; COLON POLYPOSIS; COLON RESECTION; CONFIDENCE INTERVAL; CONTROLLED STUDY; FAMILIAL ADENOMATOUS POLYPOSIS; FAT INTAKE; FATTY ACID BLOOD LEVEL; FATTY ACID METABOLISM; HUMAN; INTESTINE RESECTION; NORWAY; PHOSPHOLIPID BLOOD LEVEL; PRIORITY JOURNAL;

ADENOMATOUS POLYPOSIS COLI; ADULT; AGED; ALPHA-LINOLENIC ACID; ARACHIDONIC ACID; COLECTOMY; DOCOSAHEXAENOIC ACIDS; HUMANS; LINOLEIC ACID; MIDDLE AGED; PHOSPHOLIPIDS;

EID: 33845689193     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.22337     Document Type: Article

References (47)

1. Bennett A, Civier A, Hensby CN, Melhuish PB, Stamford IF. Measurement of arachidonate and its metabolites extracted from human normal and malignant gastrointestinal tissues. Gut 1987;28:315-18.
2. Baro L, Hermoso JC, Nunez MC, Jimenez-Rios JA, Gil A. Abnormalities in plasma and red blood cell fatty acid profiles of patients with colorectal cancer. Br J Cancer 1998;77:1978-83.
3. Mosconi C, Agradi E, Gambelta A, Bozzetti F, Galli C. Decrease of polyunsaturated fatty acids and elevation of the oleic/stearic acid ratio in plasma and red blood cell lipids of malnourished cancer patients. JPEN J Parenter Enteral Nutr 1989;13:501-4.
4. Fernandez-Banares F, Esteve M, Navarro E, Cabre E, Boix J, Abad-Lacruz A, Klaassen J, Planas R, Humbert P, Pastor C, Gassull MA. Changes of the mucosal n-3 and n-6 fatty acid status occur early in the colorectal adenoma-carcinoma sequence. Gut 1996;38:254-9.
5. Hendrickse CW, Kelly RW, Radley S, Donovan IA, Keighley MR, Neoptolemos JP. Lipid peroxidation and prostaglandins in colorectal cancer. Br J Surg 1994;81:1219-23.
6. Neoptolemos JP, Husband D, Imray C, Rowley S, Lawson N. Arachidonic acid and docosahexaenoic acid are increased in human colorectal cancer. Gut 1991;32:278-81.
7. Busstra MC, Siezen CL, Grubben MJ, van Kranen HJ, Nagengast FM, van't VP. Tissue levels of fish fatty acids and risk of colorectal adenomas: a case-control study (Netherlands). Cancer Causes Control 2003;14:269-76.
8. Bartsch H, Nair J, Owen RW. Dietary polyunsaturated fatty acids and cancers of the breast and colorectum: emerging evidence for their role as risk modifiers. Carcinogenesis 1999;20:2209-18.
9. Abir F, Alva S, Kaminski DL, Longo WE. The role of arachidonic acid regulatory enzymes in colorectal disease. Dis Colon Rectum 2005;48:1471-83.
10. Larsson SC, Kumlin M, Ingelman-Sundberg M, Wolk A. Dietary long-chain n-3 fatty acids for the prevention of cancer: a review of potential mechanisms. Am J Clin Nutr 2004;79:935-45.
11. Kinzler KW, Nilbert MC, Su LK, Vogelstein B, Bryan TM, Levy DB, Smith KJ, Preisinger AC, Hedge P, McKechnie D. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661-5.
12. Yang VW, Shields JM, Hamilton SR, Spannhake EW, Hubbard WC, Hylind LM, Robinson CR, Giardiello FM. Size-dependent increase in prostanoid levels in adenomas of patients with familial adenomatous polyposis. Cancer Res 1998;58:1750-3.
13. Chu AJ, Chou TH, Chen BD. Prevention of colorectal cancer using COX-2 inhibitors: basic science and clinical applications. Front Biosci 2004;9:2697-713.
14. Giardiello FM, Casero RA, Jr, Hamilton SR, Hylind LM, Trimbath JD, Geiman DE, Judge KR, Hubbard W, Offerhaus GJ, Yang VW. Prostanoids, ornithine decarboxylase, and polyamines in primary chemoprevention of familial adenomatous polyposis. Gastroenterology 2004;126:425-31.
15. Fujimura T, Ohta T, Oyama K, Miyashita T, Miwa K. Role of cyclooxygenase-2 in the carcinogenesis of gastrointestinal tract cancers: a review and report of personal experience. World J Gastroenterol 2006;12:1336-45.
16. Church RD, Fleshman JW, McLeod HL. Cyclo-oxygenase 2 inhibition in colorectal cancer therapy. Br J Surg 2003;90:1055-67.
17. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 2002;94:252-66.
18. Swamy MV, Cooma I, Patlolla JM, Simi B, Reddy BS, Rao CV. Modulation of cyclooxygenase-2 activities by the combined action of celecoxib and decosahexaenoic acid: novel strategies for colon cancer prevention and treatment. Mol Cancer Ther 2004;3:215-21.
19. Reddy BS, Patlolla JM, Simi B, Wang SH, Rao CV. Prevention of colon cancer by low doses of celecoxib, a cyclooxygenase inhibitor, administered in diet rich in omega-3 polyunsaturated fatty acids. Cancer Res 2005;65:8022-7.
20. Brosens LA, Iacobuzio-Donahue CA, Keller JJ, Hustinx SR, Carvalho R, Morsink FH, Hylind LM, Offerhaus GJ, Giardiello FM, Goggins M. Increased cyclooxygenase-2 expression in duodenal compared with colonic tissues in familial adenomatous polyposis and relationship to the -765G → C COX-2 polymorphism. Clin Cancer Res 2005;11:4090-6.
21. Bulow S, Bjork J, Christensen IJ, Fausa O, Jarvinen H, Moesgaard F, Vasen HF. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004;53:381-6.
22. Bjorneboe A, Soyland E, Bjorneboe GE, Rajka G, Drevon CA. Effect of dietary supplementation with eicosapentaenoic acid in the treatment of atopic dermatitis. Br J Dermatol 1987;117:463-9.
23. Harvei S, Bjerve KS, Tretli S, Jellum E, Robsahm TE, Vatten L. Prediagnostic level of fatty acids in serum phospholipids: omega-3 and omega-6 fatty acids and the risk of prostate cancer. Int J Cancer 1997;71:545-51.
24. Hjartaker A, Lund E, Bjerve KS. Serum phospholipid fatty acid composition and habitual intake of marine foods registered by a semi-quantitative food frequency questionnaire. Eur J Clin Nutr 1997;51:736-42.
25. Nordvik I, Myhr KM, Nyland H, Bjerve KS. Effect of dietary advice and n-3 supplementation in newly diagnosed MS patients. Acta Neurol Scand 2000;102:143-9.
26. Johansson L, Solvoll K, Bjørneboe GEA, Drevon CA. Dietary habits among Norwegian men and women. Scand J Nutr 1997;4:63-70.
27. Brustad M, Braaten T, Lund E. Predictors for cod-liver oil supplement use-the Norwegian women and cancer study. Eur J Clin Nutr 2004;58:128-36.
28. Esteve-Comas M, Nunez MC, Fernandez-Banares F, Abad-Lacruz A, Gil A, Cabre E, Gonzalez-Huix F, Bertran X, Gassull MA. Abnormal plasma polyunsaturated fatty acid pattern in non-active inflammatory bowel disease. Gut 1993;34:1370-3.
29. Esteve M, Navarro E, Klaassen J, Abad-Lacruz A, Gonzalez-Huix F, Cabre E, Ramos E, Condom E, Fernandez-Banares F, Pastor C, Humbert P, Marti-Rague J, et al. Plasma and mucosal fatty acid pattern in colectomized ulcerative colitis patients. Dig Dis Sci 1998;43:1071-8.
30. Esteve-Comas M, Ramirez M, Fernandez-Banares F, bad-Lacruz A, Gil A, Cabre E, Gonzalez-Huix F, Moreno J, Humbert P, Guilera M. Plasma polyunsaturated fatty acid pattern in active inflammatory bowel disease. Gut 1992;33:1365-9.
31. Geerling BJ, Houwelingen AC, Badart-Smook A, Stockbrugger RW, Brummer RJ. Fat intake and fatty acid profile in plasma phospholipids and adipose tissue in patients with Crohn's disease, compared with controls. Am J Gastroenterol 1999;94:410-7.
32. Andersen LF, Solvoll K, Drevon CA. Very-long-chain n-3 fatty acids as biomarkers for intake of fish and n-3 fatty acid concentrates. Am J Clin Nutr 1996;64:305-11.
33. Katan MB, van BA, Deslypere JP, Penders M, van Staveren WA. Biological markers of dietary intake, with emphasis on fatty acids. Ann Nutr Metab 1991;35:249-52.
34. Nkondjock A, Shatenstein B, Maisonneuve P, Ghadirian P. Specific fatty acids and human colorectal cancer: an overview. Cancer Detect Prev 2003;27:55-66.
35. Edes TE, Walk BE, Thornton WH, Jr, Fritsche KL. Essential fatty acid sufficiency does not preclude fat-soluble-vitamin deficiency in short-bowel syndrome. Am J Clin Nutr 1991;53:499-502.
36. Murphy J, Laiho K, Wootton S. Fat malabsorption in cystic fibrosis patients. Am J Clin Nutr 1999;70:943-6.
37. Nicholson ML, Neoptolemos JP, Clayton HA, Talbot IC, Bell PR. Increased cell membrane arachidonic acid in experimental colorectal tumours. Gut 1991;32:413-8.
38. Siezen CL, van Leeuwen AI, Kram NR, Luken ME, van Kranen HJ, Kampman E. Colorectal adenoma risk is modified by the interplay between polymorphisms in arachidonic acid pathway genes and fish consumption. Carcinogenesis 2005;26:449-57.
39. Stark KD, Mulvad G, Pedersen HS, Park EJ, Dewailly E, Holub BJ. Fatty acid compositions of serum phospholipids of postmenopausal women: a comparison between Greenland limit and Canadians before and after supplementation with fish oil. Nutrition 2002;18:627-30.
40. Akedo I, Ishikawa H, Nakamura T, Kimura K, Takeyama I, Suzuki T, Kameyama M, Sato S, Nakamura T, Matsuzawa Y, Kakizoe T, Otani T. Three cases with familial adenomatous polyposis diagnosed as having malignant lesions in the course of a long-term trial using docosahexanoic acid (DHA)-concentrated fish oil capsules. Jpn J Clin Oncol 1998;28:762-5.
41. Gronn M, Christensen E, Hagve TA, Christophersen BO. Effects of dietary purified eicosapentaenoic acid (20:5 (n-3)) and docosahexaenoic acid (22:6(n-3)) on fatty acid desaturation and oxidation in isolated rat liver cells. Biochim Biophys Acta 1992;1125:35-43.
42. Engler MM, Bellenger-Germain SH, Engler MB, Narce MM, Poisson JP. Dietary docosahexaenoic acid affects stearic acid desaturation in spontaneously hypertensive rats. Lipids 2000;35:1011-5.
43. Pala V, Krogh V, Muti P, Chajes V, Riboli E, Micheli A, Saadatian M, Sieri S, Berrino F. Erythrocyte membrane fatty acids and subsequent breast cancer: a prospective Italian study. J Natl Cancer Inst 2001;93:1088-95.
44. Chajes V, Hulten K, Van Kappel AL, Winkvist A, Kaaks R, Hallmans G, Lenner P, Riboli E. Fatty-acid composition in serum phospholipids and risk of breast cancer: an incident case-control study in Sweden. Int J Cancer 1999;83:585-90.
45. Chaudry A, McClinton S, Moffat LE, Wahle KW. Essential fatty acid distribution in the plasma and tissue phospholipids of patients with benign and malignant prostatic disease. Br J Cancer 1991;64:1157-60.
46. Pandey M, Sharma LB, Singh S, Shukla VK. Erythrocyte membrane fatty acid profile and saturation index in gallbladder carcinogenesis: a case-control study. World J Surg Oncol 2003;1:5.
47. Wood CB, Habib NA, Thompson A, Bradpiece H, Smadja C, Hershman M, Barker W, Apostolov K. Increase of oleic acid in erythrocytes associated with malignancies. Br Med J 1985;291:163-5.